  EGCG, as a representative of amyloid inhibitors, has shown a promising
ability against Abeta fibrillation by directly degradating the mature fibrils.
Most previous studies have been focusing on its functional mechanisms,
meanwhile its optimal dosage has been seldom considered. To solve this critical
issue, we refer to the generalized Logistics model for amyloid fibrillation and
inhibition and adopt the optimal control theory to balance the effectiveness
and cost (or toxicity) of inhibitors. The optimal control trajectory of
inhibitors is analytically solved, based on which the influence of model
parameters, the difference between the optimal control strategy and several
traditional drug dosing strategies are systematically compared and validated
through experiments. Our results will shed light on the rational usage of
amyloid inhibitors in clinic.
